Global Infectious Disease Diagnostics Market
Number of pages: 100 | Report Format: PDF | Published date: January 19, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 35.50 billion |
|
Revenue Forecast in 2030 |
US$ 45.91 billion |
|
CAGR |
2.9% |
|
Base Year for Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Product, Technology, Disease type, End user, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global infectious disease diagnostics market was valued at US$ 35.50 billion in 2021 and is expected to register a revenue CAGR of 2.9% to reach US$ 45.91 billion by 2030.
Global Infectious Disease Diagnostics Market Fundamentals
Pathogenic organisms are responsible for infectious diseases and invade the body from the outside. Infectious disease-causing pathogens include viruses, bacteria, fungi, parasites, and, in rare cases, prions. It is possible for some infectious diseases to spread from person to person. Others are spread by animals or insects. In other instances, exposure to environmental organisms or the consumption of contaminated food or water also contributes to disease.
Viral infections are brought on by viruses, which are pieces of information, DNA, or RNA enclosed in a defense mechanism (capsid). In comparison to their host cells, viruses are significantly smaller and incapable of self-replication. Once inside the host cells, they exploit the cell’s internal resources to replicate themselves.
Bacterial infections are caused due to bacteria, which are single-celled creatures that carry their information on a small bit of DNA. Similar to bacteria, there are various types of fungi. When pathogenic fungi become enlarged, they can cause disease in the host.
The symptoms of infectious diseases vary depending on the organism causing the infection, although fever and exhaustion are common. While severe life-threatening diseases may require hospitalization, mild infections may be treated with rest and home treatments. General signs and symptoms common to several infectious diseases include fever, diarrhea, fatigue, muscle aches, and coughing. Infectious diseases are usually diagnosed using one or more lab tests. The signs of disease can be identified with nose or throat swabs, blood, urine, stool, and saliva samples, taking a biopsy, or scraping a small sample of skin or other tissue, and by imaging technologies, such as X-rays, CT scans, and MRIs of affected parts of the body. Bacteria may occasionally need to be cultured (grown) from a sample in a lab to find out the infection. Some of the medications required for the treatment of infectious diseases consist of antibiotics, antifungals, and antiparasitic drugs.
[5636734]
Global Infectious Disease Diagnostics Market Dynamics
Rising prevalence of infectious diseases across developed and developing countries is the major factor for the revenue growth in the infectious disease diagnostics market. Moreover, growing awareness regarding the early diagnosis and management of infectious diseases is resulting into increasing demand for infectious disease diagnostic tests.
Government and non-government organizations across the globe are increasing funding for the diagnostic labs. Moreover, demand for point-of-care diagnostics tests is on rise. These factors are playing a significant role in the revenue growth of the infectious disease diagnostics market.
Increasing incorporation of advanced technologies in disease diagnostics and rising R&D activities focused on the development of effectual treatment solutions for infectious diseases are boosting the infectious disease diagnostics market revenue growth.
However, lack of solid reimbursement policies and high costs of diagnostics instruments are restricting the revenue growth in the infectious disease diagnostics market. Furthermore, shortage of skilled healthcare professionals in developing countries and the commercialization of diagnostics tests are also hindering the revenue growth of the infectious disease diagnostics market to some extent.
Global Infectious Disease Diagnostics Market Ecosystem
The global infectious disease diagnostics market is analyzed from five perspectives: product, technology, disease type, end-user, and region.
Infectious Disease Diagnostics Market by Product
[2794683]
Based on the product, the global infectious disease diagnostics market is segmented into instruments, reagents, and services.
The reagent segment dominates the global infectious disease diagnostics market in terms of revenue share. This is attributed to repeated purchases of the reagents. Rise in the utilization of PCR in R&D activities of the biopharmaceutical market is driving demand for reagents. Moreover, increase in the launch of newly commercialized products and development of novel reagents for diagnostics are boosting the revenue growth of this segment.
Infectious Disease Diagnostics Market by Technology
Based on the technology, the global infectious disease diagnostics market is segmented into polymerase chain reaction (PCR), immunodiagnostics, clinical microbiology, next-generation sequencing (NGS), isothermal nucleic acid amplification technology (INAAT), and others.
The polymerase chain reaction (PCR) segment accounts for the largest revenue share of the global infectious disease diagnostics market. PCR allows the identification of certain diseases that are challenging to cultivate in vitro, contributing to the segment’s revenue growth. When compared to the culture technique, PCR outcomes are significantly faster and more precise. The technique offers rapid diagnosis of bacteremia, specifically for low levels of bacteria in specimens. PCR is still considered adjunct test for most diseases, such as tuberculosis, which still relies on smear and culture. Thus, increasing demand for PCR in infectious disease diagnostics is fueling revenue growth in the segment.
Infectious Disease Diagnostics Market by Disease Type
Based on the disease type, the global infectious disease diagnostics market is segmented into hepatitis, human papillomavirus (HPV), hospital-acquired infections, tuberculosis (TB), human immunodeficiency virus (HIV), influenza, mosquito-borne diseases, and others.
The hepatitis segment accounts for the largest revenue share in the global infectious disease diagnostics market. Rising prevalence of hepatitis types B and C, leading to chronic diseases, is the major factor driving the revenue growth in the segment. According to the WHO, around 354 million individuals across the globe are living with hepatitis B and C. Rise in demand for early diagnosis and treatment of hepatitis is boosting the revenue growth for this segment. Moreover, growth in R&D activities related to hepatitis diagnosis and treatment and rising number of doses of hepatitis provided to newborn babies are propelling revenue growth in the segment.
Infectious Disease Diagnostics Market by End-user
Based on the end-user, the global infectious disease diagnostics market is segmented into hospitals & clinics, diagnostics laboratories, research institutes, and others.
The diagnostics laboratories segment accounts for the largest revenue share of the global infectious disease diagnostics market. This is attributed to rising demand for diagnostics laboratories across developed and emerging economies. Increase in the demand for decentralized testing diagnostics laboratories is also boosting revenue growth in the diagnostics laboratories segment.
Infectious Disease Diagnostics Market by Region
Based on the region, the global infectious disease diagnostics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
North America leads the global infectious disease diagnostics market, followed by Europe and Asia Pacific. Rising prevalence of infectious diseases is boosting revenue growth in the region. The Centers for Disease Control and Prevention (CDC) estimated that flu has resulted in 9 million to 41 million illnesses in the U.S. from 2010 to 2020. Rise in healthcare expenditures, well-developed healthcare infrastructure, and presence of major market players are fueling revenue growth in this region. Moreover, increase in the number of visits of patients to physician offices for infectious and parasitic diseases and rise in the need for early diagnosis of infectious diseases are helping in the revenue growth of the North America market.
Global Infectious Disease Diagnostics Market Competitive Landscape
The prominent players operating in the infectious disease diagnostics market are:
Global Infectious Disease Diagnostics Market Strategic Developments
Rising prevalence of infectious diseases and growing awareness regarding early disease diagnosis are driving the market revenue growth.
Lack of reimbursement policy and high costs of diagnostics instruments are restricting revenue growth in the global infectious disease diagnostics market.
Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton, Dickinson, and Company, and bioMérieux SA are among the key companies operating in the global infectious disease diagnostics market.
The infectious disease diagnostics market is expected to register a revenue CAGR of 2.9% during the forecast period.
The identification of a causative agent of a specific infectious disease by a series of tests is known as infectious disease diagnostics.
*Insights on financial performance are subject to the availability of information in the public domain